ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) Return on equity 2020–2025
ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-8.5%FY2025 · since FY2020: -50.1% → -8.5%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -8.5% | +80.4 pp |
| FY2024 | -88.9% | +206.8 pp |
| FY2023 | -295.6% | -147.0 pp |
| FY2022 | -148.6% | -79.3 pp |
| FY2021 | -69.3% | -19.2 pp |
| FY2020 | -50.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More ARQT financial trends
ARQT RevenueARQT Net incomeARQT Net marginARQT Gross profitARQT Gross marginARQT Operating incomeARQT Operating marginARQT Operating cash flowARQT Free cash flowARQT Capital expendituresARQT Stock buybacksARQT Dividends paidARQT Total assetsARQT Total liabilitiesARQT Shareholders’ equityARQT overview →